

## **Million Veteran Program** Washington, DC 20420



September 1, 2023

Dear Dr. Mickey Mouse,

We are writing to let you know that one of your patients, John Doe (DOB 01/01/1900), was recently identified to have a genetic variant associated with **familial hypercholesterolemia (FH)**. This variant was first found through his participation in the Million Veteran Program (MVP) research study and was then confirmed in a clinical laboratory as a part of the MVP-ROAR (Return of Actionable Results) study. A copy of the clinical variant report is enclosed. The results of a fasting lipid profile are also enclosed.

Your patient has received genetic counseling about this result from Morgan Danowski, MS, CGC, but he will probably have questions for you, too.

Patients will FH have a markedly elevated risk of atherosclerotic cardiovascular disease and require aggressive lowering of their LDL cholesterol. We have enclosed a treatment algorithm you might find helpful, based on the 2018 multisociety Guideline on the Management of Blood Cholesterol (Grundy SM, et al. Circulation 2018). You might also consider referring this patient to a preventive cardiologist, lipidologist, or other specialist with FH expertise. Because FH is inherited in an autosomal dominant manner, guidelines recommend screening of first-degree relatives (parents, siblings, children) for FH. The FH Foundation website (https://thefhfoundation.org/) includes many helpful resources for patients and providers about FH, including providers in your area who treat patients with FH.

We also invite you to contact Morgan Danowski, MS, CGC at 617-595-5635 for any additional questions you might have about these results and recommendations for next steps in clinical management. She would be happy to discuss the care of this Veteran with you further.

Sincerely,

Jason L. Vassy, M.D., M.P.H

MVP-ROAR Principal Investigator

## Familial hypercholesterolemia clinical management guidelines

Advise on lifestyle modifications to correct non-cholesterol ASCVD risk factors

Initiate treatment with high-intensity statin to lower LDL-C by ≥50%:

Atorvastatin 40-80 mg Rosuvastatin 20-40 mg

Titrate statin dose to goal LDL-C:
<100 mg/dL if no established ASCVD or other risk factors
<70 mg/dL if established ASCVD
Consider goal <70 mg/dL based on other ASCVD risk factors

If LDL-C remains above goal despite maximal tolerated statin therapy, consider addition of ezetimibe

If LDL-C remains above goal despite maximal tolerated statin and ezetimibe therapy, consider addition of PCSK9 inhibitor

ASCVD includes ACS in the last 12 months, history of MI, history of ischemic stroke, symptomatic peripheral artery disease, including aneurysm, all of atherosclerotic origin

ASCVD risk factors: Age ≥65 years, prior PCI, CABG, other evidence of CAD, diabetes mellitus; hypertension, CKD, current smoking, congestive heart failure; family history of premature ASCVD, elevated CAC score, Lp(a), or apoB; ABI <0.9

Adapted from ACC/AHA 2018 Cholesterol Clinical Practice Guidelines, Circulation 2018 and GF Watts, et al. Int J Cardiol 2014.